Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,373,892
  • Shares Outstanding, K 109,794
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.20
  • Price/Sales 5.81
  • Price/Cash Flow 17.36
  • Price/Book 4.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 6.03
  • Number of Estimates 2
  • High Estimate 6.23
  • Low Estimate 5.82
  • Prior Year 5.92
  • Growth Rate Est. (year over year) +1.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
363.14 +6.28%
on 12/19/19
396.47 -2.66%
on 01/15/20
+16.84 (+4.56%)
since 12/17/19
3-Month
294.86 +30.89%
on 10/21/19
396.47 -2.66%
on 01/15/20
+84.37 (+27.98%)
since 10/17/19
52-Week
271.37 +42.22%
on 09/27/19
442.00 -12.68%
on 03/04/19
-31.44 (-7.53%)
since 01/17/19

Most Recent Stories

More News
Regeneron Pharm Up 30.7% Since SmarTrend Uptrend Call (REGN)

SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on October 10th, 2019 at $294.47. In approximately 3 months, Regeneron Pharm has returned 30.66% as of today's recent price of $384.76....

REGN : 385.94 (+0.10%)
Growth Differentiation Factor 8, Pipeline Review, H2 2019 - Biogen Inc, PeptiDream Inc, Pfizer & Regeneron Pharmaceuticals Inc - ResearchAndMarkets.com

The "Growth Differentiation Factor 8 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

PPTDF : 51.6700 (+1.25%)
REGN : 385.94 (+0.10%)
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.

JNJ : 149.17 (+0.65%)
MRK : 90.97 (-0.23%)
NVS : 95.93 (+0.87%)
REGN : 385.94 (+0.10%)
Ophthalmic Drugs Market Size, Share, Challenges, Threats, Development and Global Trend Analysis till 2029n

A recent market research analysis titled, Ophthalmic Drugs Market offers insightful information to the clients escalating their basic leadership size explores distinct significant facets associated with...

AGN : 192.68 (-0.59%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
REGN : 385.94 (+0.10%)
SNPHF : 17.2500 (+2.68%)
SHPG : 179.20 (+4.10%)
TEVA : 10.20 (-3.95%)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Therapeutic Drugs Market Analysed by Business Growth, Development Factors and Future Trends by 2026

Ameco Research has announced the addition of the report to their offering.

AERI : 22.74 (-5.68%)
AGN : 192.68 (-0.59%)
NVS : 95.93 (+0.87%)
REGN : 385.94 (+0.10%)
SNPHF : 17.2500 (+2.68%)
VRX.TO : 30.80 (-3.33%)
Watch for Regeneron Pharm to Potentially Pullback After Gaining 1.07% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $387.42 to a high of $392.00. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

REGN : 385.94 (+0.10%)
Colorectal Cancer Therapeutics Market to reach USD 16.58 billion by 2026, Presence of Strong Oncology Portfolio to help Players Gain Competitive: Reports Fortune Business Insights(TM)

The global Colorectal Cancer Therapeutics Market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights(TM)...

BAYRY : 20.9350 (-0.21%)
LLY : 139.58 (-1.31%)
MRK : 90.97 (-0.23%)
PFE : 40.51 (-0.25%)
REGN : 385.94 (+0.10%)
TEVA : 10.20 (-3.95%)
Proliferative Diabetic Retinopathy Market 2019 : Global Industry Size, Share, Growth, Forecasts to 2026

AGN : 192.68 (-0.59%)
MRK : 90.97 (-0.23%)
MKKGY : 25.6700 (+0.10%)
NVS : 95.93 (+0.87%)
REGN : 385.94 (+0.10%)
VRX.TO : 30.80 (-3.33%)
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

SNY : 51.24 (+0.10%)
LLY : 139.58 (-1.31%)
REGN : 385.94 (+0.10%)
DERM : 19.16 (+0.03%)
Global Proliferative Diabetic Retinopathy Market 2019: Rising Trends and New Technologies 2026

The recent research report on the global presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the market.The...

AGN : 192.68 (-0.59%)
AMPE : 0.65 (+6.36%)
MKKGY : 25.6700 (+0.10%)
NVS : 95.93 (+0.87%)
PFE : 40.51 (-0.25%)
REGN : 385.94 (+0.10%)
SNPHF : 17.2500 (+2.68%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 389.09
1st Resistance Point 387.52
Last Price 385.94
1st Support Level 383.45
2nd Support Level 380.95

See More

52-Week High 442.00
Last Price 385.94
Fibonacci 61.8% 376.82
Fibonacci 50% 356.68
Fibonacci 38.2% 336.55
52-Week Low 271.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar